. Semin Thromb Hemost 31: 195?04. van Giezen JJ, Nilsson L, Berntsson P, Wissing BM, Giordanetto F, Tomlinson W et al. (2009). Ticagrelor binds to human P2Y12 independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation. J Thromb Haemost 7: 1556?565. van Giezen JJ, Sidaway J, Glaves P, Kirk I, Bj kman JA (2012). Ticagrelor inhibits adenosine uptake in vitro and enhances adenosine-mediated hyperemia responses within a canine model. J Cardiovasc Pharmacol Ther 17: 164?72. Gurbel PA, Bliden KP, Butler K, Antonino MJ, Wei C, Teng R et al. (2010). Response to ticagrelor in clopidogrel nonresponders and responders and impact of switching therapies: the RESPOND study. Circulation 121: 1188?199. Hagihara K, Kazui M, Ikenaga H, Nanba T, Fusegawa K, Takahashi M et al. (2009). Comparison of formation of thiolactones and active metabolites of prasugrel and clopidogrel in rats and dogs. Xenobiotica 39: 218?26. Husted SE, Storey RF, Bliden K, Tantry US, H mark L, Butler K et al. (2012). Pharmacokinetics and pharmacodynamics of ticagrelor in sufferers with steady coronary artery disease: benefits from the ONSET-OFFSET and RESPOND research. Clin Pharmacokinet 51: 397?09. Iy?D, Glenn JR, White AE, Fox SC, Heptinstall S (2011). Adenosine derived from ADP can contribute to inhibition of platelet aggregation inside the presence of a P2Y12 antagonist. Arterioscler Thromb Vasc Biol 31: 416?22. Jakubowski JA, Winters KJ, Naganuma H, Wallentin L (2007). Prasugrel: a novel thienopyridine antiplatelet agent. A overview of preclinical and clinical studies and also the mechanistic basis for its distinct antiplatelet profile. Cardiovasc Drug Rev 25: 357?74. Jernberg T, Payne CD, Winters KJ, Darstein C, Brandt JT, Jakubowski JA et al. (2006). Prasugrel achieves higher inhibition of platelet aggregation and also a lower price of non-responders compared with clopidogrel in aspirin-treated sufferers with stable coronary artery disease. Eur Heart J 27: 1166?173. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, NC3Rs Reporting Guidelines Working Group (2010).Azido-PEG3-alcohol Price Animal analysis: reporting in vivo experiments: the ARRIVE suggestions. Br J Pharmacol 160: 1577?579. Lemmer JH Jr (2000). Clinical knowledge in coronary bypass surgery for abciximab-treated sufferers. Ann Thorac Surg 70: S33 37. Li YG, Ni L, Brandt JT, Compact DS, Payne CD, Ernest CS 2nd et al. (2009).201732-49-2 Price Inhibition of platelet aggregation with prasugrel and clopidogrel: an integrated analysis in 846 subjects.PMID:23903683 Platelets 20: 316?27. McGrath JC, Drummond GB, McLachlan EM, Kilkenny C, Wainwright CL (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573?576.AcknowledgementsWe thank Ms Naomi Kasanuki, Yuki Yokouchi and Chiemi Koide for their professional technical assistance, as well as thank NISSEI BILIS Co., Ltd. and Security Research Institute for Chemical Compounds Co., Ltd. for their professional experiments.Conflict of interestJ. A. Jakubowski is definitely an employee of Eli Lilly and Enterprise. Other authors are workers of Daiichi Sankyo Co., Ltd.
Journal of Urban Health: Bulletin from the New York Academy of Medicine, Vol. 91, No. three doi:10.1007/s11524-013-9850-7 * 2013 The Author(s). This short article is published with open access at SpringerlinkExtreme Heat Awareness and Protective Behaviors in New York CityKathryn Lane, Katherine Wheeler, Kizzy Charles-Guzman, Munerah Ahmed, Micheline Blum, Katherine Gregory, Nathan Graber, Nancy Clark, and Thomas MatteABSTRACT Heat waves can.
